The current tools of clinical risk assessment for medulloblastoma cannot sufficiently identify patients older than 3 years who require aggressive or less-intensive radiation treatment, but considerable effort has been made to improve clinical risk stratification. The current paradigm for stratifying patients for treatment is discussed and the authors highlight that an understanding of the biology of medulloblastoma will help improve clinical risk stratification that currently under treats and over treats a significant percentage of patients.
- William R Polkinghorn
- Nancy J Tarbell
